Welcome back. Novo Nordisk gaining FDA approval for the first oral weight loss drug. Our Anakah Constantino spoke with the CEO and joins us this morning.Hey, Anakah. >> Hi, Carl. That's right.So, we're all familiar with Novo's Blockbuster Weekly injection, Mgoi. But for the very first time, patients will be able to access an oral version of that drug. It's the first ever GLP-1 pill specifically approved for obesity, and it's launching early in 2026.And Novo says it's priced at a significant discount to what ...

Core Insights - Novo Nordisk (NVO) and Amgen (AMGN) are both large-cap healthcare leaders with strong balance sheets and a history of successful drug development, making them attractive investments in the healthcare sector [2] - NVO leads in the GLP-1 market with its semaglutide products, while AMGN has a diversified portfolio across multiple therapeutic areas [3][4] - NVO's focus on diabetes and obesity treatments offers concentrated growth potential, whereas AMGN's diversification supports consistent cash flow [4] Novo Nordisk (NVO) Overview - NVO holds a 59% global market share in the GLP-1 space as of September 2025, driven by its semaglutide products [6] - The company is expanding its manufacturing capacity to strengthen its market leadership in diabetes and obesity care [7] - NVO is pursuing new indications for its semaglutide drugs, including cardiovascular (CV) and other conditions, with recent FDA approvals enhancing its growth prospects [8][9] - NVO is advancing its next-generation obesity pipeline, including CagriSema and amycretin, which are expected to enter later stages of development [10] - The company is also building its Rare Disease franchise with approvals for treatments in hemophilia A and B [11] - NVO has faced challenges, including weaker-than-expected sales and increased competition, leading to downward revisions in its 2025 guidance [13] Amgen (AMGN) Overview - AMGN's diverse portfolio includes key medicines like Evenity, Repatha, and newer drugs such as Tavneos, which are driving sales growth [14] - The acquisition of Horizon Therapeutics has expanded AMGN's rare disease business significantly [15] - AMGN's key pipeline candidate, MariTide, is being evaluated for obesity with a focus on less frequent dosing to improve patient adherence [16][17] - The company has a strong biosimilars portfolio and is developing biosimilars for major oncology drugs [19] - Despite facing pricing pressures and competition, AMGN's fundamentals are improving, with upward trends in earnings estimates for 2025 and 2026 [20][21] Comparative Analysis - NVO's shares have declined by 32% over the past six months, while AMGN's shares have increased by 19.6%, reflecting differing investor sentiments [26] - NVO currently holds a Zacks Rank 5 (Strong Sell), while AMGN has a Zacks Rank 3 (Hold), indicating a preference for AMGN among investors [28] - From a valuation perspective, NVO trades at a lower price/earnings ratio of 13.53 compared to AMGN's 15.33, suggesting that AMGN may be viewed as a more stable investment option [29]

Core Viewpoint - Novo Nordisk has received FDA approval for the first oral weight loss drug, a GLP-1 pill specifically for obesity, set to launch in early 2026 [1][2]. Group 1: Product Details - The new oral drug is priced at approximately $150 per month before insurance, which is significantly lower than existing injection options [2]. - This oral medication represents a major advancement in obesity treatment, providing patients with an alternative to injections [2]. Group 2: Market Impact - The CEO of Novo Nordisk, Mike Dutar, indicated that the approval will significantly expand the market for obesity treatments, as many individuals are hesitant to use injections due to fear of needles or societal stigma [3]. - The introduction of a pill option is expected to attract a broader patient base who may have previously avoided treatment due to the injection format [3].

Group 1 - Novo Nordisk's stock surged, with an intraday increase of over 10% following the FDA approval of its first oral GLP-1 weight loss drug, Wegovy [1][2] - The oral drug is expected to be launched in early 2026 at a cash price of $149 per month, with potential costs as low as $25 per month for insured patients [1][2] - The CEO of Novo Nordisk emphasized that Wegovy provides a new, convenient treatment option for patients, claiming no other oral GLP-1 therapy matches its weight loss effectiveness [2] Group 2 - The oral formulation is seen as the next growth engine in the weight loss drug market, with Goldman Sachs analysts predicting it could capture 24% of the global market by 2030, valued at approximately $22 billion [2] - The introduction of the oral version is expected to broaden treatment access and encourage more patients to seek treatment [2] - The active ingredient in the oral drug is the same as that in the injectable version, which may enhance patient confidence in its safety and efficacy [2]

Core Insights - The oral semaglutide (Wegovy pill) has received FDA approval, marking a significant milestone for Novo Nordisk A/S, which could be a turning point for the company [1]. Company Summary - Novo Nordisk A/S is positioned to benefit from the FDA approval of the oral semaglutide, which is expected to enhance its market presence and potentially drive revenue growth [1].

Core Viewpoint - The oral semaglutide (Wegovy pill) has gained FDA approval, marking a significant turning point for Novo Nordisk A/S [1] Group 1: FDA Approval Impact - The approval of the oral semaglutide is seen as a pivotal moment for Novo Nordisk, potentially enhancing its market position [1] Group 2: Company Background - Novo Nordisk is recognized for its innovative approaches in the pharmaceutical industry, particularly in diabetes and obesity treatments [1]

Group 1: Novo Nordisk and GLP-1 Pills - Novo Nordisk's shares increased by nearly 10% following FDA approval of the oral version of Wegovy, a GLP-1 weight loss drug, with a starting price of $149/month available in early January [2][3] - The approval gives Novo Nordisk a competitive edge over Eli Lilly, which is developing its own oral GLP-1 medication, orforglipron, expected to launch next year [3] Group 2: Warner Bros. Discovery and Paramount Skydance - Warner Bros. Discovery is in a bidding war with Netflix for its HBO parent company, indicating a significant shift in the entertainment landscape [4] - Paramount Skydance, despite losing the bidding war, is making personal guarantees from Oracle CEO Larry Ellison, who is willing to invest over $40 billion to reassure investors [5] - If Netflix fails to secure regulatory approval, Paramount Skydance could be positioned to acquire Warner Bros. Discovery, making the situation critical to monitor [6]

Group 1 - U.S. stocks experienced a decline, with the Dow Jones index falling approximately 0.1% on Tuesday [1] - Novo Nordisk A/S shares surged 8.6% to $52.26 following FDA approval of its Wegovy pill, marking the first approval of its kind globally [1] Group 2 - WW International Inc shares increased by 14.4% to $30.42 after launching an integrated GLP-1 program [2] - Lifezone Metals Ltd saw an 11.1% gain, reaching $4.43 [2] - Hycroft Mining Holding Corporation shares rose 9.1% to $26.75 [2] - Sable Offshore Corp gained 8.8% to $8.27 after receiving approval for the restart plans of the Las Flores Pipeline system [2] - Ascentage Pharma Group International shares increased by 8.4% to $28.17 [2] - Lionsgate Studios Corp shares surged 8.3% to $9.06 after expanding access to its ad-supported streaming inventory [2] - Critical Metals Corp gained 7.6% to $8.65 [2] - ZIM Integrated Shipping Services Ltd shares rose 7.4% to $21.35 after receiving acquisition proposals and evaluating offers [2] - mF International Limited shares increased by 7.1% to $21.38 [2] - Intrepid Potash Inc shares rose 7.1% to $29.06 [2] - Sellas Life Sciences Group Inc gained 6.8% to $2.82 [2] - StoneCo Ltd shares increased by 5.8% to $14.96 after the board authorized a new share repurchase program of up to R$2 billion [2] - Century Aluminum Co shares rose 5% to $39.02, with Wells Fargo analyst maintaining an Overweight rating and raising the price target from $37 to $46 [2]

Market Overview - U.S. stock markets opened cautiously on December 23rd, 2025, following a strong third-quarter GDP report, with the Dow Jones Industrial Average (DJIA) dipping slightly while the S&P 500 (SPX) and Nasdaq Composite (IXIC) rose fractionally [1][2] - The S&P 500 is just 0.3% away from its all-time closing high, indicating strong year-end rally momentum, driven by technology and industrial sectors, particularly the artificial intelligence (AI) sector [2] Economic Data - The third-quarter 2025 GDP grew at an annualized rate of 4.3%, significantly above the forecast of 3.2%, marking the highest growth rate in two years [3] - Inflation accelerated, with the price index for domestic purchases rising 3.4% compared to 2.0% in the second quarter, suggesting that the Federal Reserve may not cut interest rates in the near future [3] Upcoming Economic Indicators - Investors are awaiting key economic indicators, including November's Durable Goods Orders, Industrial Production figures, and December's Consumer Confidence survey, which is expected to rise to 91.7 from 88.7 [4] AI Sector Developments - The AI sector remains a dominant theme, with projections indicating that AI infrastructure capital expenditure could exceed $1 trillion by 2028, and major companies are investing $380 billion in 2025 for AI infrastructure [5] Company-Specific News - Nvidia (NVDA) shares rose 1.5% after the approval of high-end AI chip sales to certain customers in China [6] - Alphabet (GOOGL) gained 0.9% following its acquisition of Intersect for $4.75 billion to expand data center capacity [6] - Novo Nordisk (NVO) shares surged over 7% after U.S. regulators approved a pill version of its weight-loss drug, Wegovy [6] - Micron Technology (MU) closed up 4% and gained an additional 0.5% at Tuesday's open [6] - Oracle (ORCL) rose 3.2% on Monday but slipped 1.5% at Tuesday's open [6] Broader Market Trends - Gold futures reached $4,530 an ounce, while silver also set new record highs [7] - Crude oil prices remained stable at around $58.05 a barrel, and the yield on the U.S. 10-year Treasury note declined to 4.15% [7] Corporate Developments - Paramount Skydance Corp. shares jumped 4.3% as Larry Ellison provided a $40.4 billion guarantee for its bid for Warner Bros. Discovery [11] - Dominion Energy (D) dropped 3.7% after the pause of offshore wind project leases [11] - Uber (UBER) and Lyft (LYFT) rose 2.5% and 2.7% respectively after announcing plans for robotaxi services in London [11] - Microsoft (MSFT) received an "outperform" rating with a $625 price target, highlighting its role in AI development [11] - Tesla (TSLA) shares hit a record high of nearly $500 after a court victory regarding CEO Elon Musk's pay package [11]

PLEASED TO SAY IS THE CEO OF NOVO NORDISK, MIKE DOUSTDAR. GREAT TO HAVE YOU WITH US. JUST TO SET THE SCENE WHEN IT COMES TO THE U.S. MARKET, YOU HAVE BEEN LOSING SHERRY TO ELI LILLY FOR A COUPLE YEARS NOW. WITH THIS APPROVAL, YOU HAVE AN IMPORTANT FIRST MOVER ADVANTAGE WHEN IT COMES TO ORAL GLP-1'S.GIVEN THAT YOU EXPECT TO SELL THE PILL VERSION OF WEGOVY IN JANUARY AND ELI LILLY IS NOT DUE UNTIL MARCH, HOW DO YOU PLAN TO MAKE THE MOST OF THIS HEAD START. MIKE: THANK YOU FOR HAVING ME. AS THEY SAY, CHRISTMAS ...